In addition to improving the efficacy of IFN-α by extending its half-life, researchers have also explored tumor or specific tissue-targeted IFN-α molecules to increase the local concentration and activity while reducing systemic side effects (Table 1). This evidence concerns the gene IFNA2 and neoplasm.